2026-05-19

log/2026-05-19 — ad-hoc daily entries

Sub-file of log — see parent for index. Holds full content for one-line pointers in log.md.

[2026-05-19] brainstorm | skin-age-reversal-45-to-30

User asked for a hypothetical multi-arm intervention to reset 45-yr skin biomarkers to ~30-yr profile. Synthesised across ~60 verified atomic pages (skin-aging phenotype + 3 tissue + 5 cell-type + 5 skin-clock biomarker + retinoid class + 18 compound + 5 procedural/frontier intervention pages). No new atomic pages required to support the design — the substrate was complete after R38-R44 skin-coverage campaign.

• key constraints surfaced: Qi 2026 DHM signal uncontrolled, dermal glucosepane irreversible without age-crosslink-breakers breakthrough, no skin-biopsy data for D+Q senolytic clearance, Qi 23k MAE ~5 yr limits clock resolution

• forward-queue candidates surfaced in brainstorm § “What seeding/verification this brainstorm would justify”:

  • studies/hickson-2019-d-q-adipose-senescent-clearance.md (canonical human D+Q tissue evidence; referenced extensively; missing as atomic study page)
  • studies/farr-2024-d-q-bone-rct.md (canonical D+Q Phase 2 RCT)
  • hypotheses/skin-clock-targeting-as-aging-strategy.md (Mode B conceptual-frame; premature to seed pending Qi 2026 vehicle-controlled replication)

• highest-leverage follow-up: PDF-verifier pass on studies/qi-2026-dhm-epigenetic-skin-aging.md to confirm the −2.1 yr movement and the no-vehicle-control limitation against the published PDF — protocol’s keystone arm rests on that single study.

• 2026-05-19 verify — pentosidine.md + glucosepane.md (cross-species section) + heterocephalus-glaber.md (AGE section): Dammann 2012 fully verified against downloaded PDF (PMC3348492); Sell 1996 abstract confirmed via PMC40263 HTML (full PDF download failed); Sell 1989 confirmed via PubMed abstract (PMID 2513322); Rutter 2003 verified via PMC3561737 HTML. 7 corrections across 3 pages. Key corrections: (1) GTE did NOT reduce skin pentosidine significantly (p=NS) — vitamin E alone did (p=0.030); (2) pentosidine NOT significantly higher in Fukomys breeders (p=0.062 borderline NS) — only total AGEs, glucosepane, CML were; (3) Dammann and Sell are co-first authors; (4) per-species rate table added to pentosidine.md from Dammann 2012 Table 3; (5) n=38 total (nonbreeders 30, breeders 8) added; (6) mole-rat pentosidine rate 0.0073 added; (7) archive status corrected for Dammann 2012 (downloaded PMC3348492). Supersession check: no meta-analyses or RCTs superseding Sell 1996 or Dammann 2012 found (zero PubMed hits for relevant combinations 2019–2026). pentosidine.md flipped verified: true; glucosepane.md and heterocephalus-glaber.md verified-scope updated. → direct seed verification, not part of a numbered round

• 2026-05-19 seed — pentosidine process page + cross-species AGE kinetics extensions (NMR + glucosepane): new processes/pentosidine.md; extended processes/glucosepane.md with ‘Cross-species AGE accumulation kinetics’ section; extended model-organisms/heterocephalus-glaber.md with ‘AGE biology and glycation’ section. Prompted by user question on NMR + AGE/glucosepane gap. All new content verified: false (abstract-level; primary PDFs pending). PMIDs verified: Sell 1996 PNAS (8552666), Dammann 2012 J Gerontol (22156473), Rutter 2003 Int J Vitam Nutr Res (14743550), Sell & Monnier 1989 JBC (2513322). Key gap surfaced: zero PubMed hits for H. glaber + glycation/AGE as of 2026-05-19. → direct seed, not part of a numbered round